Abstract:
3-(4-Chloro)-4-oxo-2-thioxo-1,2,3,4-tetrahydro-quinazoline derivatives as T-type calcium channel antagonists are provided to treat neurogenic pain, epilepsy, hypertension or angina pectoris by inhibiting the T-type calcium channel without side effects such as pharmacokinetic interactions. 3-(4-chloro)-4-oxo-2-thioxo-1,2,3,4-tetrahydro-quinazoline derivatives represented by the formula(I) is used as a pharmaceutical composition, wherein X is (3-piperidin-1-yl-propyl)-amide, [3-(2-ethyl-piperidin-1-yl)-propyl]-amide, [3-(4-methyl-piperidin-1-yl)-propyl]-amide, 2-(butyl-methyl-amino)-ethyl-amide, (3-pyrrolidin-1-yl-propyl)-amide, (3-azepan-1-yl-propyl)-amide, [3-(4-ethyl-piperazin-1-yl)-propyl]-amide, [3-(benzyl-methyl-amide)-propyl]-amide or (2-dimethylamino-ethyl)-amide, and the compound represented by the formula(I) includes 3-(4-chloro-benzyl)-7-(4-methyl-piperazine-1-carbonyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one.
Abstract:
Novel 1,3-dioxoisoindole derivatives having selective antagonism of T-type calcium channel are provided to treat brain diseases including epilepsy, hypertension and angina pectoris, heart disease and nerve system pain by inhibiting the T-type calcium channel as a representative low-voltage activated calcium channel. The 1,3-dioxoisoindole derivatives represented by the formula(1) or their pharmaceutically acceptable salts are provided, wherein R1 is phenyl group or benzyl group which is substituted or unsubstituted by halogen atom, C1-C6 alkoxy group, C1-C6 alkyl group, or cyano group; R2 is a hetero ring group selected from piperidinyl group, pyrolidinyl group, morpholinyl group and piperazinyl group which is substituted or unsubstituted by C1-C6 alkyl substituent; and n is 1 or 2, provided that a compound in which R2 is morpholinyl group when R1 is C1-C6 alkyl-substituted phenyl group is excluded.
Abstract:
본 발명은 신규 3,4-다이엑소메틸렌 테트라하이드로파이란 유도체와 이의 제조방법에 관한 것으로서, 더욱 상세하게는 1-치환된-3-트리메틸실란일메틸-3,4-펜타다이엔-1-올 유도체와 알데히드 유도체를 루이스 산 촉매 하에서 반응시켜 제조된 2,6-위치에 다양한 치환체가 도입된 다음 화학식 1로 표시되는 3,4-다이엑소메틸렌 테트라하이드로파이란 유도체와 이의 제조방법에 관한 것이다.
상기 화학식 1에서, R 1 및 R 2 는 각각 수소원자, C 1 ∼C 10 의 포화 또는 불포화된 직쇄, 분쇄 또는 싸이클릭 알킬기, 및 방향족기 중에서 선택된다.
Abstract:
본 발명은 효모의 한 종류인 클루이베로마이세스 마르시아누스 ( Kluyveromyces marxianus )로부터 분리, 정제하여 얻은 카르보닐 환원효소 (Carbonyl Reaductase, CR) 및 이를 분리, 정제하는 방법에 관한 것이다. 본 발명에 의하여 얻어진 환원효소에 의한 환원반응은 미생물에 의한 환원반응 및 화학적 합성방법으로 얻어진 환원효소에 의한 환원반응보다 입체선택성이 높고, 비용과 시간이적인 측면에서 우수하다.
Abstract:
본 발명은 인듐할라이드(III)염을 사용하여 알릴알코올에서 알릴할라이드를 제조하는 방법에 관한 것으로, 인듐할라이드(III)염 (화학식 1)을 사용하여 알릴알코올(화학식 2)에서 알릴할라이드(화학식 3)를 제조(화학식 4)하는 것을 특징으로 하며, 본 발명에 의하여 출발물질인 알코올로부터 다양한 알릴할라이드를 한 단계의 반응으로 손쉽게 제조할 수 있다. (화학식 4)
상기 화학식 I ∼ IV에서, R 1 , R 2 , R 3 = 알킬기, 방향족 화합물, 고리화합물 치환기를 말하며, X는 Cl, Br, I와 같은 할로겐 원소를 말한다.
Abstract:
PURPOSE: Provided are Quinuclidine compounds which are useful for treatment of brain-nervous diseases caused by cholinergic neurotransmission such as Alzheimer's disease and a preparation method thereof. CONSTITUTION: A quinuclidine compounds of the formula (I) and pharmaceutically acceptable salts thereof are provided, wherein n is an integer of 1 to 5; R is a substituent on a benzene ring, hydrogen, F, Cl, methoxy, OH, NH2, NO2, 3,4-dimethoxy, 2,4-dimethoxy, cyano, C1-6 alkyl, 1,2 or 3 fluorine substituted C1-6 alkyl, 4-methoxybenzyloxy, t-butoxycarbonyl, C2-6 alkenyl, 1,2 or 3 fluorine substituted C2-6 alkenyl, C2-6 alkynyl, 1,2 or 3 fluorine substituted C2-6 alkynyl, and C3-7 cycloalkyl. A method for preparing the quinuclidine compounds of the formula (I) comprises reacting a compound of the formula (II) with a compound of the formula (III) or (IV), wherein R1 and R2 are independently C1-6 alkyl, aryl or arylalkyl.
Abstract:
PURPOSE: Provided is a cephem derivative which has broad range of antimicrobial activity. And its producing method is also provided. CONSTITUTION: The cephalosporin compounds represented by formula (1) and its pharmaceutically acceptable salts are produced. In the formula, R1 is hydrogen or an amine protecting group generally used in cephalosporin compounds; R2 is hydrogen or an oxim protecting group; R3 is hydrogen or a chloro group; R5 is hydrogen or an ester producing group, a salt producing atom or a carboxy protecting group; and R4 is ring substituent having Q group, in which Q is hydrogen, halogen, hydroxy, mercapto, cyano, carboxy, carboxylic acid ester, carbamoyloxymethyl, N,N-dimethylcarbamoyloxymethyl, carbamoyl, N,N-dimethylcarbamoyl, C1 to C4 alkyl, C1 to C4 alkyloxy, halogen substituted methyl, halogen substituted C1 to C4 alkyloxy, aryl or hetero ring substituent. The cephalosporin derivative of formula (1) is produced by reacting a compound of formula (7) with a compound of formula (8).